EFFECT OF CO-ENZYME Q1O ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE-2 DIABETES MELLITUS

Main Article Content

R. SUSSHMITHA
. SRIJA

Abstract

India has nearly 33 million diabetic subjects today, Prediabetes conditions like impaired glucose tolerance and impaired fasting glucose are also on the rise, indicating the possibility of further rise in the prevalence of diabetes. This study was conducted in Department of Pharmacology and Department of Medicine Bharath Institute of Higher Education and Research, Chennai, Tamilnadu during the period of August 2015 - February 2016 (6months). All the subjects were between the ages of 18-65 years. 40 subjects were selected for the study and their fasting blood glucose, blood HbA1c level, lipid profile (LDL, Triglycerides, HDL, TC), blood coenzyme Q10 level, BMI were analyzed at the beginning of the study, 12th week and 24th week. Adverse events were also noted in each visit to meet the peoples. The study showed, the Metformin with Coenzyme Q1O group, reduction in fasting blood glucose along with HbAlc level at the end of treatment period. In conclusion, coenzyme QlO along with Metformin was well-tolerated by patients with type 2 Diabetes Mell it us. With more advanced therapy for Diabetes evolving, this therapy with biguanide and coenzyme QlO, assures effective in long-term glycemic control and can provide additional benefits not only in Diabetes but as antioxidant in other diseases too.

Keywords:
Co-Enzyme, Qlo, glycemic control, Type-2 Diabetes Mellitus

Article Details

How to Cite
SUSSHMITHA, R., & SRIJA, . (2021). EFFECT OF CO-ENZYME Q1O ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE-2 DIABETES MELLITUS. UTTAR PRADESH JOURNAL OF ZOOLOGY, 42(23), 68-72. Retrieved from http://mbimph.com/index.php/UPJOZ/article/view/2609
Section
Original Research Article

References

Wilkin TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. International Journal of obesity. 2009 Jul;33(7):716-26.

Stone MA, Camosso‐Stefinovic J, Wilkinson J, De Lusignan S, Hattersley AT, Khunti K. Incorrect and incomplete coding and classification of diabetes: a systematic review. Diabetic Medicine. 2010 May;27(5):491-7.

Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, Powers AC, Rhodes CJ, Sussel L, Weir GC. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. The Journal of Clinical Endocrinology & Metabolism. 2014 Jun 1;99(6):1983-92.

Nebbioso M, Federici M, Rusciano D, Evangelista M, Pescosolido N. Oxidative stress in preretinopathic diabetes subjects and antioxidants. Diabetes technology & therapeutics. 2012 Mar 1;14(3):257-63.

Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, Bell R, Badaru A, Talton JW, Crume T, Liese AD. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. Jama. 2014 May 7;311(17):1778-86.

Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinology and Metabolism Clinics. 2010 Sep 1;39(3):481-97.

Kilic G, Alvarez-Mercado AI, Zarrouki B, Opland D, Liew CW, Alonso LC, Myers Jr MG, Jonas JC, Poitout V, Kulkarni RN, Mauvais-Jarvis F. The islet estrogen receptor-α is induced by hyperglycemia and protects against oxidative stress-induced insulin-deficient diabetes. PLoS One. 2014 Feb 3;9(2):e87941.

Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovascular diabetology. 2005 Dec;4(1):1-1.

Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001 Dec;414(6865):782-7.

Azevedo M, Alla S. Diabetes in sub-saharan Africa: kenya, mali, mozambique, Nigeria, South Africa and zambia. International journal of diabetes in developing countries. 2008 Oct;28(4):101.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May 1;27(5):1047-53.

Abbondante S, Baglietto-Vargas D, Rodriguez-Ortiz CJ, Estrada-Hernandez T, Medeiros R, LaFerla FM. Genetic ablation of tau mitigates cognitive impairment induced by type 1 diabetes. The American Journal of Pathology. 2014;184(3):819–826.

Baglietto-Vargas D, Chen Y, Suh D, et al. Short-term modern life-like stress exacerbates Aβ-pathology and synapse loss in 3xTg-AD mice. Journal of Neurochemistry. 2015; 134(5):915–926,.

Schubert M, Brazil DP, Burks DJ. et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. The Journal of Neuroscience. 2003;23(18):7084–7092.